Xenon Pharms

XENE NASDAQ
10.07
-0.44
-4.19%
Closed 16:00 07/16 EDT
Open
10.43
Prev Close
10.51
High
10.79
Low
10.02
Volume
44.61K
Avg Vol (3M)
84.17K
52 Week High
15.92
52 Week Low
5.41
% Turnover
0.17%
Market Cap
259.53M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Xenon Pharms XENE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
MORE >

Recently

Name
Price
%Change